Jeff Bradley, MD (@jeffbradleymd) 's Twitter Profile
Jeff Bradley, MD

@jeffbradleymd

Professor, University of Pennsylvania, #RadOnc, lung cancer and proton therapy specialist...Cardinals fan! Opinions are my own.

ID: 391658664

calendar_today15-10-2011 22:24:50

315 Tweet

1,1K Followers

245 Following

Jeff Bradley, MD (@jeffbradleymd) 's Twitter Profile Photo

Meaning…. Captured in a treatment plan database. So able to query any Dx or Vx vs outcome, toxicity and/or efficacy. As you know, PACIFIC captured no RT metrics

ACS Journal Cancer (@journalcancer) 's Twitter Profile Photo

Black patients remain underrepresented in clinical trials. This real-world study examines the impact of race in patients with NSCLC treated with chemoradiation and durvalumab. 🔗acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… OncoAlert #LCSM

Black patients remain underrepresented in clinical trials. This real-world study examines the impact of race in patients with NSCLC treated with chemoradiation and durvalumab. 

🔗acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn…

<a href="/OncoAlert/">OncoAlert</a> 
#LCSM
Penn Medicine MD (@pennmdforum) 's Twitter Profile Photo

Penn Radiation Oncology welcomes Dr. Jeffrey Bradley! Dr. Bradley specializes in thoracic malignancies with a focus on stereotactic body radiation therapy and proton beam therapy. Penn Medicine Jeff Bradley, MD For more info or to refer a patient: spr.ly/6013PwrXR

Penn Radiation Oncology welcomes Dr. Jeffrey Bradley! Dr. Bradley specializes in thoracic malignancies with a focus on stereotactic body radiation therapy and proton beam therapy. <a href="/PennMedicine/">Penn Medicine</a> <a href="/JeffBradleyMD/">Jeff Bradley, MD</a> 
For more info or to refer a patient: spr.ly/6013PwrXR
PTCOG-NA (@ptcogna) 's Twitter Profile Photo

First ever trial of proton therapy and immunotherapy for reirradiation of recurrent NSCLC. Phase II trial of consolidation pembrolizumab after proton reirradiation for thoracic recurrences of non-small cell lung cancer Jeff Bradley, MD Abigail T. Berman, MD, MSCE Nikhil Yegya-Raman redjournal.org/article/S0360-…

Paige Taylor (@mppaigetaylor) 's Twitter Profile Photo

Anyone following #ProtonTherapy clinical trials knows how exciting this is! This trial has finally reached accrual due to the dedication of Zhongxing Liao, MD Jeff Bradley, MD, NRG Oncology and IROC staff, and the many participating institutions. Well done. Can’t wait to see the data!

Drew Moghanaki 🐕 (@drewmoghanaki) 's Twitter Profile Photo

Jeff Ryckman Teoman Yanmaz Stephen V Liu, MD Do you know if PAC2 had a cross over design? I’m sure Jeff Bradley, MD can confirm. Recall, Durva isn’t a standard of care for progression during or after CRT. Those who progressed (in either arm) very likely got something else.

Stephen V Liu, MD (@stephenvliu) 's Twitter Profile Photo

Dr. Jeff Bradley, MD presents results from PACIFIC-2 at #ELCC24. Included pts with unresectable stage III NSCLC with randomization to chemoradiation with concurrent durvalumab/placebo followed by durvalumab/placebo consolidation. Note this was done before OS from PACIFIC known.

Dr. <a href="/JeffBradleyMD/">Jeff Bradley, MD</a> presents results from PACIFIC-2 at #ELCC24. Included pts with unresectable stage III NSCLC with randomization to chemoradiation with concurrent durvalumab/placebo followed by durvalumab/placebo consolidation. Note this was done before OS from PACIFIC known.
Jeff Bradley, MD (@jeffbradleymd) 's Twitter Profile Photo

We have many ongoing trials testing the hypothesis that IO during CRT improves outcomes in Stage III unresectable lung cancer. Some have completed accrual and we await events prior to analyzing and reporting. We will get more answers.

OncLive.com (@onclive) 's Twitter Profile Photo

Concurrent Durvalumab/CRT Does Not Confer Significant Survival Advantage in Unresectable Stage III NSCLC @myesmo Jeff Bradley, MD Penn Medicine #ELCC24 #lcsm onclive.com/view/concurren…

Jeff Bradley, MD (@jeffbradleymd) 's Twitter Profile Photo

Whoa… completely different groups. No patients in PACIFIC were ‘operable’ by any of the neoadj trial criteria. PAC2 patients were even more advanced stage than PACIFIC, more T4 stage patients, median PTV was 450cc. Apples and watermelons my friend